Scancell Holdings (FRA:SCP) Cash-to-Debt : 0.66 (As of Oct. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Scancell Holdings Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Scancell Holdings's cash to debt ratio for the quarter that ended in Oct. 2023 was 0.66.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Scancell Holdings couldn't pay off its debt using the cash in hand for the quarter that ended in Oct. 2023.

The historical rank and industry rank for Scancell Holdings's Cash-to-Debt or its related term are showing as below:

FRA:SCP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.66 Med: No Debt Max: No Debt
Current: 0.66

During the past 13 years, Scancell Holdings's highest Cash to Debt Ratio was No Debt. The lowest was 0.66. And the median was No Debt.

FRA:SCP's Cash-to-Debt is ranked worse than
82.3% of 1537 companies
in the Biotechnology industry
Industry Median: 6.49 vs FRA:SCP: 0.66

Scancell Holdings Cash-to-Debt Historical Data

The historical data trend for Scancell Holdings's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Scancell Holdings Cash-to-Debt Chart

Scancell Holdings Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

27.80

2.67

1.51

1.02

Scancell Holdings Semi-Annual Data
	Apr14	Oct14	Apr15	Oct15	Apr16	Oct16	Apr17	Oct17	Apr18	Oct18	Apr19	Oct19	Apr20	Oct20	Apr21	Oct21	Apr22	Oct22	Apr23	Oct23
Cash-to-Debt	Get a 7-Day Free Trial															4.47	1.51	2.54	1.02	0.66

Competitive Comparison of Scancell Holdings's Cash-to-Debt

For the Biotechnology subindustry, Scancell Holdings's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Scancell Holdings's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Scancell Holdings's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Scancell Holdings's Cash-to-Debt falls into.

Scancell Holdings Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Scancell Holdings's Cash to Debt Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	22.624	/	(0.348	+	21.837)
	=	1.02

Scancell Holdings's Cash to Debt Ratio for the quarter that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.086	/	(0.353	+	22.503)
	=	0.66

Scancell Holdings (FRA:SCP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Scancell Holdings Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Scancell Holdings's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Scancell Holdings (FRA:SCP) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scancell Holdings PLC (FRA:SCP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SCLP.GB:UK SCLP:UK

Address

Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD

Website

https://www.scancell.co.uk

Scancell Holdings PLC is engaged in the discovery and development of novel vaccines for the treatment of cancer. The company is exploiting the unrivalled potential of the immune system to seek out and destroy cancer using two proprietary immuno-oncology platforms: ImmunoBody and Moditope. Its potent innovative DNA-based ImmunoBody therapies generate ultra-high avidity T cell responses that target and eliminate cancerous tumors. Its Moditope platform technology overcomes the immune suppression induced by tumors themselves, allowing activated T cells to seek out and kill tumor cells that would otherwise be hidden from the immune system.

Scancell Holdings (FRA:SCP) Headlines

No Headlines